Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Boehringer Ingelheim
Harvard Business School
Colorcon
Moodys

Last Updated: August 8, 2022

Investigational Drug Information for LY2606368


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for LY2606368?

LY2606368 is an investigational drug.

There have been 16 clinical trials for LY2606368. The most recent clinical trial was a Phase 2 trial, which was initiated on April 10th 2018.

The most common disease conditions in clinical trials are Neoplasms, Central Nervous System Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and National Cancer Institute (NCI).

There are three US patents protecting this investigational drug and seventy international patents.

Recent Clinical Trials for LY2606368
TitleSponsorPhase
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsEli Lilly and CompanyPhase 1
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsSt. Jude Children's Research HospitalPhase 1
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialEli Lilly and CompanyPhase 1

See all LY2606368 clinical trials

Clinical Trial Summary for LY2606368

Top disease conditions for LY2606368
Top clinical trial sponsors for LY2606368

See all LY2606368 clinical trials

US Patents for LY2606368

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY2606368 See Plans and Pricing 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate Eli Lilly and Company (Indianapolis, IN) See Plans and Pricing
LY2606368 See Plans and Pricing Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA) See Plans and Pricing
LY2606368 See Plans and Pricing 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-- carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts Eli Lilly and Company (Indianapolis, IN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Boehringer Ingelheim
Harvard Business School
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.